$4.92
5.58% yesterday
Nasdaq, Dec 04, 10:20 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US75629V1044
Symbol
RXRX

Recursion Pharmaceuticals Stock price

$4.92
-0.08 1.60% 1M
+0.01 0.20% 6M
-1.84 27.22% YTD
-2.21 31.00% 1Y
-4.19 45.99% 3Y
-26.38 84.28% 5Y
-26.38 84.28% 10Y
-26.38 84.28% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.26 5.58%
ISIN
US75629V1044
Symbol
RXRX
Industry

New AI Insights on Recursion Pharmaceuticals Insights AI Insights on Recursion Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$1.9b
Net debt
positive
Cash
$659.8m
Shares outstanding
491.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
58.6 | 35.1
EV/Sales
44.0 | 26.3
EV/FCF
negative
P/B
2.5
Financial Health
Equity Ratio
71.4%
Return on Equity
-44.8%
ROCE
-58.1%
ROIC
-106.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$43.7m | $73.1m
EBITDA
$-646.4m | $-648.4m
EBIT
$-723.6m | $-672.1m
Net Income
$-715.5m | $-803.5m
Free Cash Flow
$-447.7m
Growth (TTM | estimate)
Revenue
-33.0% | 24.2%
EBITDA
-70.4% | -40.9%
EBIT
-83.6% | -40.3%
Net Income
-89.4% | -73.3%
Free Cash Flow
-34.7%
Margin (TTM | estimate)
Gross
-59.0%
EBITDA
-1,479.5% | -887.5%
EBIT
-1,656.2%
Net
-1,637.8% | -1,099.7%
Free Cash Flow
-1,024.7%
More
EPS
$-1.6
FCF per Share
$-0.9
Short interest
29.6%
Employees
800
Rev per Employee
$70.0k
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

7x Buy
50%
7x Hold
50%

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
44 44
33% 33%
100%
- Direct Costs 69 69
64% 64%
159%
-26 -26
213% 213%
-59%
- Selling and Administrative Expenses 220 220
61% 61%
504%
- Research and Development Expense 470 470
78% 78%
1,076%
-646 -646
70% 70%
-1,479%
- Depreciation and Amortization 77 77
421% 421%
177%
EBIT (Operating Income) EBIT -724 -724
84% 84%
-1,656%
Net Profit -716 -716
89% 89%
-1,638%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Positive
The Motley Fool
about 21 hours ago
Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.
Neutral
GlobeNewsWire
4 days ago
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GM...
Positive
The Motley Fool
11 days ago
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Employees 800
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today